NIMH: RAISE Study to Have Immediate Clinical Impact

In a Science Update, the National Institute of Mental Health (NIMH) reports that Medicaid services is already taking steps to implement ‚Äúcoordinated specialty care‚ÄĚ (CSC) in response to the RAISE study released last week. ‚ÄúThe RAISE initiative has shown that coordinated specialty care for first episode psychosis is better than the standard care offered in community clinics. However, covering the cost of coordinated specialty care can be challenging. When Medicaid agrees to pay for effective treatment programs, patients in need benefit.‚ÄĚ

Nardo on RAISE study: ‚ÄúSpin is for Politicians‚ÄĚ

Dr. Mickey Nardo adds to the ongoing discussion about the RAISE study results. He writes: ‚ÄúIf there is ‚Äėspin‚Äô in the reporting of this study, we need to know about it. I personally think that it‚Äôs more important for RAISE to be reported completely and honestly than whether it comes out like they [or I] want it to come out. We don‚Äôt need some sanitized version of RAISE to tell us we need to turn our attention to a full bodied approach to the treatment of First Episode psychotic patients. We all already know that. What we do need is to have our confidence restored in our research community ‚Äď that they will honestly and clearly report their findings whether they are clean as a whistle or an unholy mess.‚ÄĚ

“Medication for Schizophrenia: Less is More?”

Neuroskeptic weighs in on the controversy over the lack of antipsychotic dose data in the RAISE study and the misleading media coverage. He points out that one of the treatment interventions was a computerized medication management system called COMPASS, which recommends doctors use lower doses than they otherwise might.

New York Times Issues Correction on RAISE Study Report

Last Tuesday, The New York Times and several other outlets (including Mad In America) reported on the highly-touted results of a study on psychosocial treatment for patients diagnosed with schizophrenia. Now, claims made about the study, which the ‚ÄėTimes called ‚Äúthe most rigorous trial to date,‚ÄĚ are coming under increased scrutiny.

RAISE Study Out Of Sync With Media Reports

Writing on his 1 Boring Old Man blog, Dr. Mickey Nardo reflects on the media frenzy around the RAISE study and asks why the prescription data has not been released. He adds skepticism about the political motives of the potentially overblown results, which he sees as a clear push for increased mental health funding.

Confusion Over Antipsychotic Dosing Data in RAISE Study

Yesterday, the New York Times reported that schizophrenia patients in an experimental treatment program (RAISE) who experienced better outcomes had been on lower doses of antipsychotics than normal. However, the article published in the American Journal of Psychiatry on Tuesday did not divulge any data on the varying antipsychotic drug doses in the different study groups.

Landmark Schizophrenia Study Recommends More Therapy

Results of a large government-funded study call into question current drug heavy approaches to treating people diagnosed with schizophrenia. The study, which the New York Times called ‚Äúby far the most rigorous trial to date conducted in the United States,‚ÄĚ found that patients who received smaller doses of antipsychotic drugs with individual talk therapy, family training, and support for employment and education had a greater reduction in symptoms as well as increases in quality of life, and participation in work and school than those receiving the current standard of care.